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Abstract The aim of the study presented here was to
determine the prevalence of Chlamydia pneumoniae
versus Mycoplasma pneumoniae infections in paediatric
patients with community-acquired pneumonia. A total of
50 patients (mean age, 5.5 years; median, 3.9 years) with
community-acquired pneumonia were enrolled. Four
patients were found to have Chlamydia pneumoniae
infection (1 culture positive, 1 PCR positive and 2
serology positive) and 16 patients had Mycoplasma
pneumoniae infection (2 PCR positive, 4 PCR and
serology positive, 10 serology positive), including three
patients with coinfection. The rates of Mycoplasma
pneumoniae infection were 22%, 35% and 40% in
children aged 1–3, >3–7 and >7 years, respectively.
Acute Chlamydia pneumoniae infection was substantially
less common than Mycoplasma pneumoniae infection in
our study cohort.
Introduction
Little is known about the frequency of community-
acquired pneumonia (CAP) caused by Chlamydia pneu-
moniae in paediatric patients in Europe, and the results
published so far are conflicting. Prevalence rates of
between 6% and 23% have been reported so far for
Chlamydia pneumoniae found in the nasopharynx of
healthy children using the polymerase chain reaction
(PCR) [1, 2]. Furthermore, in studies using combinations
of PCR, culture and serology, Chlamydia pneumoniae has
been identified as the presumptive causative agent of CAP
in children to various degrees [3, 4, 5, 6, 7].
The goal of the present study was to estimate the
prevalence of Chlamydia pneumoniae infections in com-
parison with Mycoplasma pneumoniae infections in
paediatric patients with CAP admitted to the University
Children’s Hospital, which provides basic paediatric care
for the region of Basel, Switzerland.
Patients and Methods
The study was performed from March 1999 to February 2000, and
all patients aged 1–18 years who were hospitalised with a diagnosis
of radiographically proven CAP were eligible for participation. To
avoid interference of maternally derived IgG antibodies with the
serological diagnosis, infants were not enrolled. Subjects were also
excluded for the following reasons: known immunodeficiency,
treatment with immunoglobulins during the previous 3 months, or
chronic underlying disease. The diagnosis of pneumonia required
characteristic clinical findings as proposed by the World Health
Organization [8], i.e. tachypnoea, respiratory distress, cyanosis,
feeding difficulty, absence of wheezing, and radiological confir-
mation. Chest radiographs were assessed by the consultant
radiologist who was unaware of the microbiological diagnosis.
The study protocol was approved by the ethical commission of the
University of Basel Medical Faculty.
Nasopharyngeal aspirates and oropharyngeal specimens were
obtained for PCR using Dacron swabs from each patient on
admission, and one further oropharyngeal specimen was obtained
for culture (Chlamydia pneumoniae). Nasopharyngeal aspirates and
oropharyngeal specimens were placed into transport medium (0.9%
sodium-chloride solution) and stored at 4C until PCR was
performed (within 48 h). DNA was extracted and purified by
proteinase K digestion followed by phenol-chloroform extraction
and ethanol precipitation. For Chlamydia pneumoniae, a semi-
nested PCR was performed using the primer pair HL/HR-1 and
HM/HR-1 as described previously [9]. PCR of Mycoplasma
pneumoniae was performed using the method described by Ieven
et al. [10] with the primer pair MP P1-1 and MP P1-2. In-house
validation tests have been performed for both PCR methods.
Cycloheximide-treated HEp 2 cells were used for culture of
Chlamydia pneumoniae. Confirmation of suspicious cells was
performed using fluorescent antibody staining with an in-house
Chlamydia pneumoniae-specific monoclonal antibody [11].
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Acute (on admission) and convalescent (4–6 weeks post-
admission) serum samples were collected. Antibody titres (IgG,
IgM and IgA) for Chlamydia pneumoniae were measured using a
microimmunofluorescence assay that includes positive and nega-
tive controls (Serofia; Savyon Diagnostics, Switzerland). For
Mycoplasma pneumoniae, a semiquantitative enzyme-linked im-
munosorbent assay (SeroMP; Savyon Diagnostics) was performed
(IgG and IgM). Antibody values were determined using the
reference line method, which allows the calculation of elevations
in antibody levels. The antigen used was the P1 membrane protein.
Serum samples that were positive for IgM but negative for IgG by
enzyme-linked immunosorbent assay were also analyzed using the
particle agglutination test and immunoblotting (Virotech, Ger-
many).
Statistical analysis was performed using SPSS version 10.0 for
Windows. Independent proportions were compared using Fisher’s
exact test or the Mantel-Haenszel chi-square analysis, as appropri-
ate. A P level<0.05 was considered significant.
Results and Discussion
During the 12-month study period, 64 patients hospi-
talised with CAP were eligible for study participation and
the parents of 50 of these patients provided informed
consent for them to participate. Patients were aged 1.2–
15.3 years (mean, 5.5 years; median, 3.9 years) and 29
were female. Nasopharyngeal aspirates and oropharyn-
geal specimens were available from all study participants
and acute and convalescent serum specimens were
obtained from 49 and 46 subjects, respectively. Five
patients had received antibiotic treatment for at least 48 h
before hospitalisation. Mean temperature on admission
was 39.2C (range, 36.4–40.2C). Mean peripheral leu-
cocyte count on admission was 18.0109/l (median,
16.7109/l; range, 4.6–44109/l) and the mean C-reactive
protein level was 140 mg/l (median, 124 mg/l; range, 3–
567 mg/l). One of 40 blood cultures was positive and
grew Streptococcus pneumoniae.
Overall, four patients were found to have Chlamydia
pneumoniae infection (Table 1). Interestingly, three of the
four patients with Chlamydia pneumoniae infection also
had signs of concomitant Mycoplasma pneumoniae
infection. In addition, three study subjects (aged 3.6,
11.1 and 12.4 years) had serological evidence of past
Chlamydia pneumoniae infection. Three of the four
patients with acute Chlamydia pneumoniae infection,
including two with Chlamydia pneumoniae and Myco-
plasma pneumoniae coinfection, showed lobar consolida-
tion involving several adjacent segments. Their C-
reactive protein values on admission were 152 mg/ml,
139 mg/ml and 258 mg/ml. Of those three patients, two
(both with Chlamydia pneumoniae and Mycoplasma
pneumoniae coinfection) had pneumonia with effusion.
One patient with Chlamydia pneumoniae and Mycoplas-
ma pneumoniae coinfection had an interstitial pneumonia
and a C-reactive protein value of 42 mg/ml.
Overall, 16 patients, including three with concomitant
Chlamydia pneumoniae infection, were diagnosed as
having acute Mycoplasma pneumoniae infections. The
incidence of Mycoplasma pneumoniae as the cause of
CAP increased according to the age of the patients.
Thirteen cases were diagnosed during the cold season
(October–March) without any apparent clusters. Using
enzyme-linked immunoassay, 17 patients were found to
have signs of acute Mycoplasma pneumoniae infection. In
eight of these subjects, the diagnosis relied on the
presence of IgM antibodies only. Confirmatory particle
agglutination test and immunoblot assay could be
performed in seven cases; all samples tested positive
with the particle agglutination test (1:40) and four were
also confirmed by immunoblot. This decreases the total
number of serologically confirmed cases of acute Myco-
plasma pneumoniae infection to 14 (Table 2). All patients
recovered without significant sequelae, including a 14-
month-old girl with Mycoplasma pneumoniae infection
who required 2 days of intensive care treatment for
imminent respiratory failure.
Radiographic patterns of pneumonia did not correlate
with aetiological diagnosis nor did the clinical character-
istics, such as maximum body temperature, C-reactive
protein values and leucocyte counts (data not shown).
In this study of 50 children and adolescents with CAP
examined for signs of Chlamydia pneumoniae and
Mycoplasma pneumoniae infection, we found Mycoplas-
ma pneumoniae infection to be frequent (32%) and its
relative frequency tended to increase according to age.
PCR and serology findings were concordant in 25% of
cases and discordant in 75%; PCR missed 10 of the 16
Table 1 Detection of Chlamydia pneumoniae and Mycoplasma pneumoniae in children and adolescents with CAP according to patient
age
Age in year No. with C. pneumoniae a No. with M. pneumoniae b
PCR + Sero + Cult + Any + PCR + PCR + Sero + Any +
(Sero/cult –) (PCR/cult –) (Sero/PCR –) (Sero –) (Sero +) (PCR –)
1–3 (n=18) 1 1 – 2 2 1 1 4
>3–7 (n=17) – – 1 1 – 1 5 6
>7–16 (n=15) – 1 – 1 – 2 4 6
Total (n=50) 1 2 1 4 2 4 10 16
PCR, polymerase chain reaction; Sero, serology; Cult, culture
a Acute C. pneumoniae infection: positive culture or PCR or specific serological criteria, i.e. a single positive IgM (1:20), IgA (1:20) or
IgG (1:512) titre or a 4-fold IgG titre rise in paired serum specimens [14]
b Acute M. pneumoniae infection: positive PCR (NP or OP) or positive IgM antibodies (10 U/ml) in acute and/or convalescent serum
specimens or a significant IgG antibody increase (4-fold) in paired serum specimens
743
total cases. Similarly, Waris et al. [12] were unable to
demonstrate the presence of Mycoplasma pneumoniae by
PCR in 10 of 20 children with serologically confirmed
Mycoplasma pneumonia. Interestingly, only patients with
negative IgG antibodies in the acute phase had a positive
PCR result. In accordance with this observation, three of
our four PCR-positive patients were positive for IgM but
negative for IgG antibodies against Mycoplasma pneu-
moniae in their acute serum specimens. This observation
suggests that Mycoplasma pneumoniae organisms may be
harboured in the upper respiratory tract preferentially
during the very early phase of infection.
It has been shown previously that a subset of patients
with pneumonia and a corresponding positive culture or
PCR result for Mycoplasma pneumoniae lack an antibody
response to the organism [3]. The reasons for this are
unknown. It is notable that both of our patients who were
positive for Mycoplasma pneumoniae by PCR but lacking
an antibody response were rather young (2.8 and 1.9
years). This suggests that the serological antibody
response to Mycoplasma pneumoniae may mature with
age.
In contrast to Mycoplasma pneumoniae, the rate of
infection with Chlamydia pneumoniae was low in our
study cohort (8%). Moreover, two of the four cases were
diagnosed based on demonstration of the organism in the
upper respiratory tract without a concomitant antibody
response in acute or convalescent serum specimens. This
raises doubts about the quality of the PCR technique we
used [13] and/or the aetiological role of Chlamydia
pneumoniae in two of our cases, decreasing the rate of
Chlamydia pneumoniae infection to 4%. Similarly, in a
previous study conducted in Germany, a rate of 5.6% was
found for Chlamydia pneumoniae infection [2]. In
contrast, several other studies identified Chlamydia
pneumoniae as the cause of CAP at a higher rate, i.e. in
15–30% of children [3, 5, 6, 7]. The significant differ-
ences among the relative frequencies of Mycoplasma
pneumoniae and Chlamydia pneumoniae in association
with CAP from study to study may be attributable to
variable age groups, the kinds of diagnostic procedures
used and the presence or absence of local outbreaks in the
respective communities during the investigation period
[2]. No such outbreak occurred during the course of our
study.
Interestingly, three of our four cases with demonstrable
Chlamydia pneumoniae colonization and/or infection had
evidence of simultaneous Mycoplasma pneumoniae coin-
fection. This observation has been described before [3, 4,
6]. It raises the question of whether one pathogen simply
facilitates the penetration of the other or whether both
organisms act independently to cause the respiratory tract
infection.
No specific radiological feature or laboratory param-
eter was found that allowed us to distinguish patients with
Mycoplasma pneumoniae or Chlamydia pneumoniae
infection from those without a known cause for pneumo-
nia, which is in accordance with previous studies [4, 6].
This highlights the need for specific microbiological tests
capable of identifying patients with Mycoplasma pneu-
moniae or Chlamydia pneumoniae infection who may
benefit from specific antibiotic treatment.
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